Healthy Aging as Black Adults, In It Together: a Comparative Effectiveness Study of Chronic Pain and Cognitive Decline
Launched by MASSACHUSETTS GENERAL HOSPITAL · Jan 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to compare two different programs designed to help older Black adults who are experiencing chronic pain and early signs of cognitive decline, which means some memory or thinking skills are starting to fade. The two programs being studied are called Mindfulness-Based Cognitive Therapy with Walking (MBCT+w) and Active Living Every Day (ALED). Researchers want to see how well these programs improve physical health, thinking abilities, and emotional well-being in participants. After completing the programs, the participants will be checked again after six months to see if the benefits last.
To join the study, participants must be Black adults aged 50 or older who have had chronic pain in their muscles or joints for over three months and have reported early cognitive decline. They should also be able to speak and read English and be cleared by a doctor to participate. Participants who are currently taking certain medications or have specific health issues may not be eligible. If chosen, participants can expect to engage in activities related to the programs while being supported by researchers, and their progress will be monitored throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Black adults, male and females, age 50 or older
- • Have nonmalignant musculoskeletal chronic pain for more than three months
- • Reports early cognitive decline (subjective and objective)
- • Telephone Interview for Cognitive Status-41 score greater than or equal to 31
- • Functional Activities Questionnaire score less than 9
- • English fluency/literacy
- • Free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain stable dose
- • Cleared by medical doctor for study participation and no self-reported concerns about physical functioning on the revised Physical Activity Readiness Questionnaire (PAR-Q; score 0)
- Exclusion Criteria:
- • Diagnosed with dementia or neurodegenerative disease
- • Regular use of nonpharmacological pain management
- • Diagnosed with serious mental illness or substance abuse
- • Current suicidal ideation on self-report
- • Engagement of regular exercise for more than 30 minutes daily
- • Unable to walk
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Olivia Okereke, MD, MS
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported